

## Zombie NIR™ Fixable Viability Kit

<b>Catalog# / Size</b>	423105 / 100 tests 423106 / 500 tests
<b>Regulatory Status</b>	RUO
<b>Other Names</b>	Fixable Dye, Fixable Viability Dye
<b>Description</b>	Zombie NIR™ is an amine reactive fluorescent dye that is non-permeant to live cells, but permeant to the cells with compromised membranes. Thus, it can be used to assess live vs. dead status of mammalian cells. Zombie NIR™ is a polar water soluble dye, providing red fluorescence, making it suitable for multi-color detection.

### Product Details

---

<b>Preparation</b>	Zombie NIR™ Fixable Viability kit is composed of lyophilized Zombie NIR™ dye and anhydrous DMSO. For reconstitution, bring the kit to room temperature; add 100 µl of DMSO to one vial of Zombie NIR™ dye until fully dissolved. 100 tests = 1 vial of Zombie NIR™ + DMSO, 500 tests = 5 vials of Zombie NIR™ + DMSO.
<b>Storage &amp; Handling</b>	Store kit at -20°C upon receipt. Do not open vials until needed. Once the DMSO is added to the Zombie NIR™ dye, use immediately, or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.
<b>Application</b>	<a href="#">FC - Quality tested</a>
<b>Recommended Usage</b>	<p>Each lot of this product is quality control tested by immunofluorescent staining with flow cytometric analysis.</p> <p>For flow cytometry, the suggested dilution is 1:100-1:1000 for 1-10 million cells. It is recommended that the reagent be titrated for optimal performance for each application, as optimal dosage varies with cell type.</p>
<b>Excitation Laser</b>	Red Laser (633 nm)
<b>Application Notes</b>	<p><b>Standard Cell Staining Protocol:</b></p> <ol style="list-style-type: none"><li>1. Prior to reconstitution, spin down the vial of lyophilized reagent in a microcentrifuge to ensure the reagent is at the bottom of the vial.</li><li>2. For reconstitution, pre-warm the kit to room temperature; add 100 µl of DMSO to one vial of Zombie NIR™ dye and mix until fully dissolved</li><li>3. Wash cells with PBS buffer (no Tris buffer and protein free).</li><li>4. Dilute Zombie NIR™ dye at 1:100-1000 in PBS. Resuspend 1-10 x 10<sup>6</sup> cells in diluted 100 µl Zombie NIR™ solution. To minimize background staining of live cells, titrate the amount of dye and/or number of cells per 100 µl for optimal performance. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.</li></ol> <p><b>Note:</b> Don't use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS. <b>Note:</b> The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.</p> <ol style="list-style-type: none"><li>5. Incubate the cells at room temperature, in the dark, for 15-30 minutes.</li><li>6. Wash one time with 2 ml BioLegend's Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing serum or BSA.</li><li>7. Continue performing antibody staining procedure as desired.</li><li>8. Cells can be fixed with paraformaldehyde or methanol prior to permeabilization or can be analyzed without fixation.</li></ol> <p><b>No-wash Sequential Staining Protocol:</b></p> <ol style="list-style-type: none"><li>1. Wash cells with PBS buffer (no Tris buffer and protein free).</li><li>2. For reconstitution, pre-warm the kit to room temperature; add 100 µl of DMSO to one vial of Zombie NIR™ dye and mix until fully dissolved</li><li>3. Determine the total µl volume of antibody cocktail previously titrated and optimized for the assay</li></ol>

that will be added to each vial/well of cells based on a final volume of 100  $\mu$ l. Subtract that antibody volume from the 100  $\mu$ l total staining volume intended for the assay. In the remaining volume, dilute Zombie NIR™ dye at 1:100-1000 in PBS as determined by prior optimization at that volume. For example, if you are adding 20  $\mu$ l of antibody cocktail for a 100  $\mu$ l total staining volume, use 80  $\mu$ l of Zombie NIR™ solution. Resuspend 1-10 x 10<sup>6</sup> cells in the appropriate volume of Zombie NIR™ solution. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.

**Note:** Don't use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.

**Note:** The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.

4. Incubate for 10-15 minutes at RT, protected from light. Without washing the cells, add the cell surface antibody cocktail and incubate for another 15-20 minutes.
5. Add 1-2 mL Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing BSA or serum. Centrifuge to pellet.
6. Continue with normal fixation and permeabilization procedure. If planning to skip fixation and analyze cells live, complete an additional wash step to minimize any unnecessary background of the live cells.

**Notes:** If the cell type in use cannot tolerate a protein-free environment, then titrate the Zombie NIR™ dye in the presence of the same amount of BSA/serum as will be present in the antibody staining procedure. A higher amount of Zombie NIR™ may be required since the BSA/serum will react with and bind up some proportion of the Zombie NIR™.

Zombie NIR™ dye is excited by the red laser and has fluorescence emission maximum at 746 nm. If using in a multi-color panel design, filter optimization may be required depending on other fluorophores used. Zombie NIR™ dye has similar emission to APC/Cy7.

#### Additional Product Notes

View more applications data for this product in our [Scientific Poster Library](#).

#### Application References

(PubMed link indicates BioLegend citation)

1. McMaster SR, *et al.* 2015. *PLoS One*. 10:115725. [PubMed](#)
2. Prado-Garcia H, *et al.* 2015. *Anticancer Res*.35:1529. [PubMed](#)
3. Rodriguez-Rodriguez N, *et al.* 2015. *J Immunol*. 194:4207. [PubMed](#)
4. Flies DB, *et al.* 2015. *J Immunol*. 194:5294. [PubMed](#)

#### Product Citations

1. Headley M, *et al.* 2016. *Nature*. 531:513-517. [PubMed](#)
2. Wang L, *et al.* 2020. *Front Cell Dev Biol*. 0.745138889. [PubMed](#)
3. Iyer S, *et al.* 2021. *Cancer Discov*. 0.725. [PubMed](#)
4. Komuczki J, *et al.* 2019. *Immunity*. 50:1289. [PubMed](#)
5. Rad S M AH, *et al.* 2020. *PLoS One*. 15:e0232915. [PubMed](#)
6. Kim MY, *et al.* 2021. *JCI Insight*. 6:. [PubMed](#)
7. Martínez-Vélez N, *et al.* 2022. *Mol Cancer Ther*. 21:471. [PubMed](#)
8. Baratchart E, *et al.* 2022. *PLoS Comput Biol*. 18:e1009839. [PubMed](#)
9. Luo J, *et al.* 2022. *J Nanobiotechnology*. 20:228. [PubMed](#)
10. Rosina M, *et al.* 2022. *Cell Metab*. 34:533. [PubMed](#)
11. Hsu MA, *et al.* 2022. *Cancer Immunol Immunother*. :. [PubMed](#)
12. Zheng J, *et al.* 2022. *Front Pharmacol*. 13:866228. [PubMed](#)
13. Liu Y, *et al.* 2022. *Signal Transduct Target Ther*. 7:347. [PubMed](#)
14. Sheikh BN, *et al.* 2020. *Nat Cell Biol*. 22:828. [PubMed](#)
15. Pathak JL, *et al.* 2021. *Front Cell Dev Biol*. 628139:9. [PubMed](#)
16. Jiang C, *et al.* 2020. *Int J Biol Sci*. 2.802083333. [PubMed](#)
17. Qiu J, *et al.* 2020. *Cell Rep*. 33:108465. [PubMed](#)
18. Sagami S, *et al.* 2017. *PLoS One*. 10.1371/journal.pone.0169681. [PubMed](#)
19. Lentucci C, *et al.* 2017. *J Biol Chem*. 292:2754-2772. [PubMed](#)
20. Montes de Oca M, *et al.* 2016. *Cell Rep*. 17:399-412. [PubMed](#)
21. Marco Barros R, *et al.* 2016. *Cell*. 167: 203-218. [PubMed](#)
22. Gibb D, *et al.* 2016. *EBioMedicine*. 9: 77-86. [PubMed](#)
23. Kallemeijn WW, *et al.* 2019. *Cell Chem Biol*. 26:892. [PubMed](#)
24. Kollareddy M, *et al.* 2017. *Cancer Lett*. 10.1016/j.canlet.2017.05.027. [PubMed](#)
25. Ajoge HO, *et al.* 2022. *Viruses*. 14:. [PubMed](#)
26. Tan L, *et al.* 2022. *Biochem Biophys Rep*. 32:101351. [PubMed](#)
27. Li Q, *et al.* 2022. *Cell Rep*. 40:111308. [PubMed](#)
28. He C, *et al.* 2022. *Sci Adv*. 8:eabm4552. [PubMed](#)
29. Otano I, *et al.* 2021. *Nat Commun*. 12:7296. [PubMed](#)
30. Zhou J, *et al.* 2021. *Int J Med Sci*. 18:3516. [PubMed](#)
31. Landry LG, *et al.* 2021. *Bio Protoc*. 11:e3883. [PubMed](#)
32. Barros-Martins J, *et al.* 2021. *Nat Med*. 27:1525. [PubMed](#)
33. Nordengrün M, *et al.* 2021. *Front Immunol*. 12:651060. [PubMed](#)
34. Roberts A, *et al.* 2021. *Sci Rep*. 11:4030. [PubMed](#)
35. Ma Q, *et al.* 2021. *Clin Transl Immunology*. 10:e1300. [PubMed](#)
36. Aguilera T, *et al.* 2016. *Nat Commun*. 7:13898. [PubMed](#)
37. Jimenez-Duran G, *et al.* 2020. *EBioMedicine*. 61:103039. [PubMed](#)
38. Li JY, *et al.* 2020. *J Clin Invest*. 130:1767. [PubMed](#)
39. Kilens S, *et al.* 2018. *Nat Commun*. 9:360. [PubMed](#)
40. Merz SF, *et al.* 2019. *Nat Commun*. 10:2312. [PubMed](#)

41. Barry KC, *et al.* 2018. Nat Med. 24:1178. [PubMed](#)
42. Karlen SJ, *et al.* 2018. J Neuroinflammation. 15:344. [PubMed](#)
43. Vishnoi M, *et al.* 2018. Cancer Res. 78:5349. [PubMed](#)
44. Sauter M, *et al.* 2022. iScience. 25:103677. [PubMed](#)
45. Stegelmeier AA, *et al.* 2022. Biomedicines. 10:. [PubMed](#)
46. Chen L, *et al.* 2022. Mol Ther Oncolytics. 24:522. [PubMed](#)
47. Sneller MC, *et al.* 2022. Nature. 606:375. [PubMed](#)
48. Hamminger P, *et al.* 2021. J Autoimmun. 119:102610. [PubMed](#)
49. Hu W, *et al.* 2021. Nat Immunol. 22:1163. [PubMed](#)
50. Schalbetter SM, *et al.* 2022. Sci Adv. 8:eabi6672. [PubMed](#)
51. Abou-Hamad J, *et al.* 2022. iScience. 25:105524. [PubMed](#)
52. Agudelo M, *et al.* 2021. J Exp Med. :218. [PubMed](#)
53. Gaebler C, *et al.* 2021. Nature. 639:591. [PubMed](#)
54. Olingy C, *et al.* 2017. Sci Rep. 10.1038/s41598-017-00477-1. [PubMed](#)
55. AC Belkina, JE Snyder-Cappione 2017. Cytometry A. 91:175-179. [PubMed](#)
56. Kodumudi KN, *et al.* 2019. Front Immunol. 10:1939. [PubMed](#)
57. Liu HJ, *et al.* 2018. JCI Insight. 3. [PubMed](#)
58. Zou L, *et al.* 2022. Brain Behav Immun. 100:10. [PubMed](#)
59. Son ET, *et al.* 2021. J Clin Invest. 131:. [PubMed](#)
60. Majstrowicz K, *et al.* 2021. J Cell Sci. 134:. [PubMed](#)
61. Daniel S, *et al.* 2021. Infect Immun. 89:e0016521. [PubMed](#)
62. van der Heide V, *et al.* 2022. Cell Rep. :110508. [PubMed](#)
63. Michaud D, *et al.* 2022. Front Immunol. 12:745873. [PubMed](#)
64. Nagatake T, *et al.* 2022. Mucosal Immunol. 15:289. [PubMed](#)
65. Watters JM, *et al.* 2021. Biochem Biophys Res Commun. 534:773. [PubMed](#)
66. Fitzgerald AA, *et al.* 2021. J Immunother Cancer. 9:. [PubMed](#)
67. Bouffi C, *et al.* 2015. J Immunol. 195: 2683-2695. [PubMed](#)
68. Higuchi T, *et al.* 2015. Cancer Immunol Res. 3: 1257 - 1268. [PubMed](#)
69. Woodruff MC, *et al.* 2020. Nat Immunol. 1.920833333. [PubMed](#)
70. Xu AQ, *et al.* 2020. Elife. 9:00. [PubMed](#)
71. Si Y, *et al.* 2020. Sci Adv. 6:eaba0995. [PubMed](#)
72. Pan H, *et al.* 2020. Mol Psychiatry. . [PubMed](#)
73. Guarnaccia AD, *et al.* 2021. Cell Rep. 108636:34. [PubMed](#)
74. Garcia Nores GD, *et al.* 2018. Nat Commun. 9:1970. [PubMed](#)
75. Verma M, *et al.* 2018. Cell Stem Cell. 23:530. [PubMed](#)
76. Weisberg SP, *et al.* 2020. Cell Reports. 29(12):3916-3932.e5.. [PubMed](#)
77. Fukushima T, *et al.* 2019. Cell Rep. 29:4144. [PubMed](#)
78. Hering L, *et al.* 2021. Int J Mol Sci. 22:. [PubMed](#)
79. Halim L, *et al.* 2022. Front Immunol. 13:836549. [PubMed](#)
80. Hemkemeyer SA, *et al.* 2020. J Biol Chem. 296:100136. [PubMed](#)
81. Massafra V, *et al.* 2021. J Immunol. 207:493. [PubMed](#)
82. Agudelo M, *et al.* 2022. J Exp Med. 219:. [PubMed](#)
83. Glaubitz J, *et al.* 2022. Nat Commun. 13:4502. [PubMed](#)
84. Woodruff MC, *et al.* 2022. Nature. .: [PubMed](#)
85. Patricio DO, *et al.* 2022. Front Immunol. 13:1042463. [PubMed](#)
86. Ostendorf BN, *et al.* 2020. Nat Med. 26:1048. [PubMed](#)
87. Akiyama H, *et al.* 2020. J Virol. . [PubMed](#)
88. Sperber HS, *et al.* 2020. FASEB J. 14615:34. [PubMed](#)
89. Moreau GB, *et al.* 2020. Am J Trop Med Hyg. 103:1215. [PubMed](#)
90. Kienzl M, *et al.* 2020. Oncoimmunology. 9:1776059. [PubMed](#)
91. Jenkins RW, *et al.* 2018. Cancer Discov. 8:196. [PubMed](#)
92. Retamal-Díaz A, *et al.* 2017. Front Immunol. . 10.3389/fimmu.2017.01523. [PubMed](#)
93. Wlodarska M *et al.* 2017. Cell host & microbe. 22(1):25-37 . [PubMed](#)
94. Beatson RE, *et al.* 2021. Cell Rep Med. 2:100473. [PubMed](#)
95. Mahmoud W, *et al.* 2021. Cell Tissue Res. Online ahead of print. [PubMed](#)
96. Cousin N, *et al.* 2021. Cancer Res. 81:4133. [PubMed](#)
97. Chan JA, *et al.* 2020. Cell Rep Med. 1:100157. [PubMed](#)
98. Michaud D, *et al.* 2020. Cytokine. 125:154817. [PubMed](#)
99. Simonneau M, *et al.* 2018. Oncotarget. 9:36457. [PubMed](#)
100. Koizumi SI, *et al.* 2018. Nat Commun. 9:5344. [PubMed](#)
101. Miller EB, *et al.* 2021. J Neuroinflammation. 18:235. [PubMed](#)
102. Mills C, *et al.* 2022. Cells. 11:. [PubMed](#)
103. Pettinato G, *et al.* 2021. Sci Adv. 7:. [PubMed](#)
104. Godoy-Pacheco A, *et al.* 2022. Oncol Lett. 24:288. [PubMed](#)
105. Rao X, *et al.* 2022. Cell Death Dis. 13:891. [PubMed](#)
106. Sato R, *et al.* 2020. Int Immunol. 499:32. [PubMed](#)
107. Aregger M, *et al.* 2020. Nat Metab. 0.429861111. [PubMed](#)
108. Alshetaiwi H, *et al.* 2020. Sci Immunol. 5:00. [PubMed](#)
109. PRADO-GARCIA H, *et al.* 2015. Anticancer Res. 35:1529. [PubMed](#)
110. Lisk C, *et al.* 2020. Front Immunol. 1.329166667. [PubMed](#)
111. Yang S, *et al.* 2019. Nat Commun. 10:2782. [PubMed](#)
112. Casella G, *et al.* 2017. Sci Rep. . 10.1038/s41598-017-16702-w. [PubMed](#)
113. Adamik J, *et al.* 2022. Nat Commun. 13:5184. [PubMed](#)
114. Sodji QH, *et al.* 2022. Cancer Res Commun. 2:725. [PubMed](#)
115. Zhang Z, *et al.* 2021. Acta Pharm Sin B. 11:1965. [PubMed](#)
116. Mahadevan NR, *et al.* 2021. Cancer Discov. 11:1952. [PubMed](#)
117. Alansary M, *et al.* 2021. Dent Traumatol. 37:90. [PubMed](#)
118. Le X, *et al.* 2021. J Thorac Oncol. 16:583. [PubMed](#)
119. Song D, *et al.* 2021. Sci Rep. 11:22966. [PubMed](#)
120. Aires V, *et al.* 2021. Front Immunol. 12:684430. [PubMed](#)

121. Choi JE, *et al.* 2021. *Nat Metab.* 3:182. [PubMed](#)
122. Ajina R, *et al.* 2021. *Cancer Immunol Res.* 9:386. [PubMed](#)
123. Steinbach K, *et al.* 2016. *J Exp Med.* 213: 1571 - 1587. [PubMed](#)
124. Bogie JF, *et al.* 2020. *Ther Adv Chronic Dis.* 11:2040622320947378. [PubMed](#)
125. Xie Z, *et al.* 2020. *Light Sci Appl.* 0.486805556. [PubMed](#)
126. Wang Z, *et al.* 2021. *bioRxiv.* . [PubMed](#)
127. Wang K, *et al.* 2018. *Medicine (Baltimore).* 97:e0710. [PubMed](#)
128. Schadt L, *et al.* 2020. *Cell Reports.* 29(5):1236-1248.e7.. [PubMed](#)
129. Grandclaudon M, *et al.* 2019. *Cell.* 179:432. [PubMed](#)
130. Littwitz-Salomon E, *et al.* 2021. *Nat Commun.* 12:5376. [PubMed](#)
131. Thyrsted J, *et al.* 2021. *iScience.* 24:103300. [PubMed](#)
132. Basu A, *et al.* 2021. *Cancer Immunol Res.* Online ahead of print. [PubMed](#)
133. Viant C, *et al.* 2021. *J Exp Med.* 218:. [PubMed](#)
134. Nakajima T, *et al.* 2021. *J Exp Med.* 218:. [PubMed](#)
135. Jie X, *et al.* 2022. *J Immunother Cancer.* 10:. [PubMed](#)
136. Ferrer-Font L, *et al.* 2021. *Curr Protoc.* 1:e222. [PubMed](#)
137. Li Y, *et al.* 2022. *J Neuroinflammation.* 19:261. [PubMed](#)
138. Woodruff M, *et al.* 2020. *medRxiv.* . [PubMed](#)
139. McHugh D, *et al.* 2020. *Life Sci Alliance.* 3:00. [PubMed](#)
140. Tavazoie MF, *et al.* 2018. *Cell.* 172:825. [PubMed](#)
141. English KG, *et al.* 2022. *Biomedicines.* 10:. [PubMed](#)
142. Yang J, *et al.* 2022. *Microbiome.* 10:149. [PubMed](#)
143. Stinson WA, *et al.* 2022. *JCI Insight.* 7:. [PubMed](#)
144. Kim S, *et al.* 2022. *Redox Biol.* 54:102347. [PubMed](#)
145. Luo J, *et al.* 2022. *J Nanobiotechnology.* 20:228. [PubMed](#)
146. Zeng Q, *et al.* 2022. *Front Immunol.* 13:740805. [PubMed](#)
147. Christopher GA, *et al.* 2021. *Biomolecules.* 12:. [PubMed](#)
148. Cho A, *et al.* 2021. *Nature.* Online ahead of print. [PubMed](#)
149. Clapes T, *et al.* 2021. *Nat Cell Biol.* 23:704. [PubMed](#)
150. Johnson AM, *et al.* 2020. *J Immunol.* 204:2295. [PubMed](#)
151. Thompson EA, *et al.* 2021. *Cell Rep.* 108863:34. [PubMed](#)
152. Espinoza J, *et al.* 2017. *Oxidative Medicine and Cellular Longevity.* 10.1155/2017/6781872. [PubMed](#)
153. Pinder C, *et al.* 2017. *J Immunol.* 10.4049/jimmunol.1701253. [PubMed](#)
154. Popay TM, *et al.* 2021. *Elife.* 10:. [PubMed](#)
155. Wan G, *et al.* 2021. *Sci Rep.* 11:22121. [PubMed](#)
156. Hills LB, *et al.* 2021. *J Immunol.* 206:89. [PubMed](#)
157. Kuhn JA, *et al.* 2021. *Elife.* 10:. [PubMed](#)
158. Bosnjak B, *et al.* 2021. *Front Immunol.* 12:772240. [PubMed](#)
159. Xu Y, *et al.* 2021. *Front Immunol.* 12:666991. [PubMed](#)
160. Zhang H, *et al.* 2021. *Cell Rep.* 36:109708. [PubMed](#)
161. Zhu S, *et al.* 2022. *J Oncol.* 2022:8724933. [PubMed](#)
162. Liu Y, *et al.* 2022. *Front Oncol.* 12:1037934. [PubMed](#)
163. Scharer CD, *et al.* 2020. *Nat Commun.* 3989:11. [PubMed](#)
164. Rodríguez-Rodríguez N, *et al.* 2015. *J Immunol.* 194:4207. [PubMed](#)
165. Nagatake T, *et al.* 2018. *Int Immunol.* 30:471. [PubMed](#)
166. Ito Y, *et al.* 2018. *Cell.* 174:636. [PubMed](#)
167. Lim JME, *et al.* 2022. *Cell Rep Med.* 3:100793. [PubMed](#)
168. Vanekova L, *et al.* 2022. *Methods Protoc.* 5:. [PubMed](#)
169. Elias G, *et al.* 2022. *Elife.* 11:. [PubMed](#)
170. Cohen CA, *et al.* 2021. *Nat Commun.* 12:4678. [PubMed](#)
171. Ruibal P, *et al.* 2016. *Nature.* 533: 100-104. [PubMed](#)
172. Muthalagu N, *et al.* 2020. *Cancer Discov.* 1.022222222. [PubMed](#)
173. Evgin L, *et al.* 2020. *Nat Commun.* 2.671527778. [PubMed](#)
174. Hemkemeyer SA, *et al.* 2020. *J Biol Chem.* . [PubMed](#)
175. van Vloten JP, *et al.* 2019. *Mol Ther Methods Clin Dev.* 13:154. [PubMed](#)
176. Akuffo AA, *et al.* 2018. *J Biol Chem.* 293:6187. [PubMed](#)
177. Morganti JM, *et al.* 2019. *J Neuroinflammation.* 16:98. [PubMed](#)
178. McGinnis CS, *et al.* 2019. *Nat Methods.* 1.096527778. [PubMed](#)
179. Günther T, *et al.* 2019. *PLoS Pathog.* 15:e1007838. [PubMed](#)
180. Fujimoto N, *et al.* 2020. *PLoS Biol.* 18:e3000704. [PubMed](#)
181. Meyrath M, *et al.* 2020. *Nat Commun.* 2.564583333. [PubMed](#)
182. Luo G, *et al.* 2021. *Sci Rep.* 11:7841. [PubMed](#)
183. Braun DA, *et al.* 2021. *Cancer Cell.* 39:632. [PubMed](#)
184. Cui Z, *et al.* 2021. *Cell Death Dis.* 12:775. [PubMed](#)
185. Mudd PA, *et al.* 2022. *Cell.* 185:603. [PubMed](#)
186. Valestrand L, *et al.* 2022. *Am J Pathol.* . [PubMed](#)
187. Espinal A, *et al.* 2022. *Int J Mol Sci.* 23:. [PubMed](#)
188. Evgin L, *et al.* 2022. *Sci Transl Med.* 14:eabn2231. [PubMed](#)
189. Jalloh S, *et al.* 2022. *PLoS Pathog.* 18:e1010479. [PubMed](#)
190. Soley BDS, *et al.* 2020. *Br J Pharmacol.* 177:3535. [PubMed](#)
191. Lo CH, *et al.* 2021. *Sci Rep.* 6055:11. [PubMed](#)
192. Salazar Y, *et al.* 2020. *J Clin Invest.* 3560:130. [PubMed](#)
193. Bhattacharya P, *et al.* 2020. *Elife.* 9:00. [PubMed](#)
194. Grubišić V, *et al.* 2020. *Cell Rep.* 32:108100. [PubMed](#)
195. Shim K, *et al.* 2017. *Mol Ther.* 10.1016/j.ymthe.2017.01.023. [PubMed](#)
196. Tomić A, *et al.* 2016. *PLoS Pathog.* 12:e1006015. [PubMed](#)
197. Filiano A, *et al.* 2016. *Nature.* 535:425-429. [PubMed](#)
198. Armbruster N, *et al.* 2016. *J Immunol.* 196: 1284 - 1292. [PubMed](#)
199. Ramachandran P, *et al.* 2019. *Nature.* 575:512. [PubMed](#)

200. Xueyang Yu *et al.* 2017. *Immunity*. 47(5):903-912 . [PubMed](#)
201. Nagatake T, *et al.* 2018. *J Allergy Clin Immunol*. 142:470. [PubMed](#)
202. Waight JD, *et al.* 2018. *Cancer Cell*. 33:1033. [PubMed](#)
203. Tajima M, *et al.* 2022. *Curr Protoc*. 2:e540. [PubMed](#)
204. Qadir AS, *et al.* 2021. *iScience*. 24:103348. [PubMed](#)
205. Lozano-Ojalvo D, *et al.* 2021. *Cell Rep*. 36:109570. [PubMed](#)
206. Dieterle ME, *et al.* 2021. *Elife*. 10:. [PubMed](#)
207. Sharma V, *et al.* 2021. *ACR Open Rheumatol*. 3:277. [PubMed](#)
208. Clement CC, *et al.* 2021. *Immunity*. 54:721. [PubMed](#)
209. Zhang YN, *et al.* 2021. *Sci Adv*. 7:eabj3107. [PubMed](#)
210. Manouchehri N, *et al.* 2021. *Proc Natl Acad Sci U S A*. 118:. [PubMed](#)
211. Mohammadi MR, *et al.* 2021. *Commun Biol*. 4:685. [PubMed](#)
212. Noort RJ, *et al.* 2021. *Front Cell Dev Biol*. 9:659397. [PubMed](#)
213. Cloarec R, *et al.* 2016. *PLoS One*. 11: 0160176. [PubMed](#)
214. Rouleau N, *et al.* 2020. *Immunohorizons*. 0.695833333. [PubMed](#)
215. Rizvi F, *et al.* 2021. *Nat Commun*. 0.925694444. [PubMed](#)
216. Herland A, *et al.* 2020. *Nat Biomed Eng*. 4:421. [PubMed](#)
217. Oherle K, *et al.* 2020. *Immunity*. 52:275. [PubMed](#)
218. Zhang Y, *et al.* 2018. *Front Microbiol*. 9:2967. [PubMed](#)
219. Grajchen E, *et al.* 2020. *J Neuroinflammation*. 0.863888889. [PubMed](#)
220. Wang Z, *et al.* 2021. *Nature*. 592:616. [PubMed](#)
221. Ramos MIP, *et al.* 2021. *Elife*. 10:. [PubMed](#)
222. Su Y, *et al.* 2021. *Clin Cancer Res*. :clincanres.2241.2021. [PubMed](#)
223. Dudek M, *et al.* 2021. *Nature*. 592:444. [PubMed](#)
224. Jacobsen H, *et al.* 2021. *Nat Commun*. 12:4957. [PubMed](#)
225. Cillo AR, *et al.* 2021. *Cell Rep Med*. 2:100476. [PubMed](#)
226. Janssen JJE, *et al.* 2022. *Am J Physiol Endocrinol Metab*. 322:E141. [PubMed](#)
227. Wang Z, *et al.* 2022. *J Exp Med*. 219:. [PubMed](#)
228. He Y, *et al.* 2022. *Cells*. 11:. [PubMed](#)
229. Karanika S, *et al.* 2022. *Front Immunol*. 13:972266. [PubMed](#)
230. Luo L, *et al.* 2021. *J Neuroinflammation*. 18:27. [PubMed](#)
231. Suzuki T, *et al.* 2017. *Cell Rep*. 18(8):2045-2057. [PubMed](#)
232. McMaster S, *et al.* 2015. *PLoS One*. 10:115725. [PubMed](#)
233. Ghezraoui H, *et al.* 2018. *Nature*. 560:122. [PubMed](#)
234. Manuszak C, *et al.* 2020. *J Biol Methods*. 7:e131. [PubMed](#)
235. McKenzie MD, *et al.* 2019. *Cell Stem Cell*. 25:258. [PubMed](#)
236. Zischke J, *et al.* 2017. *PLoS Pathogens*. 13(6):e1006454. [PubMed](#)
237. Reuschl AK, *et al.* 2022. *Cell Rep*. 39:110650. [PubMed](#)
238. Tang JS, *et al.* 2022. *Front Immunol*. 13:946713. [PubMed](#)
239. Wang Z, *et al.* 2021. *Nature*. 595:426. [PubMed](#)
240. Mumby MJ, *et al.* 2021. *J Virol*. 95:e0058821. [PubMed](#)
241. Chou TW, *et al.* 2021. *Cell Death Dis*. 12:756. [PubMed](#)
242. Leary N, *et al.* 2022. *J Extracell Vesicles*. 11:e12197. [PubMed](#)
243. Hobbs BE, *et al.* 2021. *Pathogens*. 10:. [PubMed](#)
244. Fan ZP, *et al.* 2021. *Front Immunol*. 12:743354. [PubMed](#)
245. Lien TS, *et al.* 2021. *Front Immunol*. 12:618577. [PubMed](#)
246. Phan TS, *et al.* 2021. *Sci Adv*. 7:. [PubMed](#)
247. Flies D, *et al.* 2015. *J Immunol*. 194:5294. [PubMed](#)
248. Hering L, *et al.* 2020. *Front Immunol*. 11:747222222. [PubMed](#)
249. Korin B, *et al.* 2020. *Sleep*. :43. [PubMed](#)
250. Santopaolo M, *et al.* 2021. *Front Immunol*. 609406:12. [PubMed](#)
251. Daniels M, *et al.* 2017. *Sci Rep*. 10.1038/s41598-017-17387-x. [PubMed](#)
252. Renner K, *et al.* 2020. *Cell Reports*. 29(1):135-150.e9.. [PubMed](#)
253. Donlan AN, *et al.* 2021. *JCI Insight*. 6: . [PubMed](#)
254. Lisk C, *et al.* 2021. *Front Immunol*. 12:624197. [PubMed](#)
255. Wang R, *et al.* 2022. *J Immunother Cancer*. 10:. [PubMed](#)
256. Denoth-Lippuner A, *et al.* 2021. *Cell Stem Cell*. 28:2020. [PubMed](#)
257. Zhang Y, *et al.* 2022. *Mater Today Bio*. 15:100317. [PubMed](#)
258. Smith KJ, *et al.* 2022. *PLoS Biol*. 20:e3001554. [PubMed](#)
259. Madsen CS, *et al.* 2022. *Commun Biol*. 5:888. [PubMed](#)
260. Maas RR, *et al.* 2021. *Nat Protoc*. 16:4692. [PubMed](#)
261. Lee HY, *et al.* 2021. *Curr Protoc*. 1:e272. [PubMed](#)
262. Mujal AM, *et al.* 2022. *Cancer Immunol Res*. 10:403. [PubMed](#)
263. Chou DB, *et al.* 2022. *Nat Commun*. 13:6021. [PubMed](#)
264. Gaebler C, *et al.* 2020. *bioRxiv*. . [PubMed](#)
265. Shimada BK, *et al.* 2020. *Immunohorizons*. 0.55625. [PubMed](#)
266. Jeffery H, *et al.* 2017. *Clin Exp Immunol*. 10.1111/cei.12940. [PubMed](#)
267. Hosking M, Flynn C, Whitton J 2016. *PLoS Pathog*. 12: 1005861. [PubMed](#)
268. Bryan AF, *et al.* 2020. *Nucleic Acids Res*. 48:2924. [PubMed](#)
269. Sontheimer-Phelps A, *et al.* 2019. *Cell Mol Gastroenterol Hepatol*. 9:507. [PubMed](#)
270. Han P, *et al.* 2020. *Sci Adv*. 6:eaaz1580. [PubMed](#)
271. Eckert EC, *et al.* 2020. *Mol Ther Oncolytics*. 0.710416667. [PubMed](#)
272. Chakraborty A, *et al.* 2022. *Methods Mol Biol*. 2442:565. [PubMed](#)
273. Li X, *et al.* 2022. *Oncoimmunology*. 11:2118210. [PubMed](#)
274. Kiesel VA, *et al.* 2022. *Front Oncol*. 12:767479. [PubMed](#)
275. Gutierrez-Prat N, *et al.* 2022. *Life Sci Alliance*. 5:. [PubMed](#)
276. Viant C, *et al.* 2020. *Cell*. 183:1298. [PubMed](#)
277. Heckler M, *et al.* 2021. *Cancer Discov*. Online ahead of prin. [PubMed](#)
278. Maller O, *et al.* 2020. *Nat Mater*. 20:548. [PubMed](#)
279. Chou DB, *et al.* 2020. *Nat Biomed Eng*. 0.440277778. [PubMed](#)

280. Wachowska M, *et al.* 2020. *Cancer Immunol Immunother.* 69:1101. [PubMed](#)
281. Gangoso E, *et al.* 2021. *Cell.* 184:2454. [PubMed](#)
282. Sibling E, *et al.* 2021. *Cells.* 10:. [PubMed](#)
283. Qin J, *et al.* 2020. *Cancer Immunol Res.* 8:1426. [PubMed](#)
284. Spiljar M, *et al.* 2021. *Cell Metab.* 33:2231. [PubMed](#)
285. Kastenschmidt JM, *et al.* 2021. *Cell Rep.* 35:108997. [PubMed](#)
286. Kerdidani D, *et al.* 2022. *J Exp Med.* 219:. [PubMed](#)
287. Sibling E, *et al.* 2022. *Cancers (Basel).* 14:. [PubMed](#)
288. Spath S, *et al.* 2022. *iScience.* 25:104998. [PubMed](#)
289. Farrand K, *et al.* 2022. *Curr Protoc.* 2:e482. [PubMed](#)
290. Clutton G, *et al.* 2016. *Sci Rep.* 6:30749. [PubMed](#)
291. Binnewies M, *et al.* 2019. *Cell.* 177:556. [PubMed](#)
292. Muchowicz A, *et al.* 2017. *Eur J Cancer.* 10.1016/j.ejca.2017.06.004. [PubMed](#)
293. Quijano-Rubio A, *et al.* 2022. *Nat Biotechnol.* Online ahead of print. [PubMed](#)
294. Patterson DG, *et al.* 2021. *J Immunol.* 207:1798. [PubMed](#)
295. Zhang N, *et al.* 2022. *Front Immunol.* 13:926368. [PubMed](#)
296. Cho A, *et al.* 2022. *J Exp Med.* 219:. [PubMed](#)
297. Celas DP, *et al.* 2022. *STAR Protoc.* 3:101464. [PubMed](#)
298. Erens C, *et al.* 2022. *Biomedicines.* 10:. [PubMed](#)
299. Zhou P, *et al.* 2022. *Sci Transl Med.* :eabi9215. [PubMed](#)
300. Sauler M, *et al.* 2022. *Nat Commun.* 13:494. [PubMed](#)
301. Guarnaccia AD, *et al.* 2021. *STAR Protoc.* 2:101000. [PubMed](#)
302. Zhang L, *et al.* 2021. *Mol Ther.* 29:744. [PubMed](#)
303. Gamradt S, *et al.* 2021. *iScience.* 24:103312. [PubMed](#)
304. Li H, *et al.* 2021. *Signal Transduct Target Ther.* 6:389. [PubMed](#)
305. Goddery EN, *et al.* 2021. *Front Immunol.* 12:726421. [PubMed](#)
306. Xie Z, *et al.* 2020. *Light Sci Appl.* 9:161. [PubMed](#)
307. Dar HH, *et al.* 2021. *Redox Biol.* 45:102045. [PubMed](#)

## Antigen Details


---

**Biology Area** Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience

**Gene ID** NA

## Product Data

---



One day old C57BL/6 mouse splenocytes were stained with Zombie NIR™ and analyzed before fixation (purple) or after fixation and permeabilization (red). Cells alone, without Zombie NIR™ staining, are indicated in black.

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
 Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587